Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell<img src=”https://s.w.org/images/core/emoji/16.0.1/72×72/2122.png” alt=”™” class=”wp-smiley”> Allogeneic T Cell Platform – NEWSnet – News… as it used to be
